Skip to content

IOVANCE BIOTHERAPEUTICS, INC.

IOVA

CIK 0001425205

← back to feed
Revenue (TTM)
$248.16M
+60.6% YoY Q1 Apr 2026
Net Income (TTM)
−$398.12M
−5.1% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.16
+14.8% YoY Q1 Apr 2026
Gross Margin
27.3%
Q1 Apr 2026
Operating Margin
-165.6%
Q1 Apr 2026
Net Margin
-160.4%
Q1 Apr 2026
Free Cash Flow (TTM)
−$420.52M
Q1 Apr 2026
Cash
$196.51M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
446.5M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings